$10.65▴ 6.55%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-47.99MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-100.0%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Keros Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-3.22
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-572.1%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$14.54M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.